MedTrace Logo

Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer

NCT00066391 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-09-24

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Combining irinotecan with cisplatin may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining irinotecan with cisplatin in treating patients who have locally advanced or metastatic penile cancer.

Conditions

  • Penile Cancer

Interventions

DRUG

cisplatin

DRUG

irinotecan hydrochloride

PROCEDURE

neoadjuvant therapy

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Christine Theodore, MD · Gustave Roussy, Cancer Campus, Grand Paris

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2006-01-31

Countries

  • Belgium
  • France
  • Hungary
  • Netherlands
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00066391 on ClinicalTrials.gov